Skip to main content
SpringerLink
Log in

Lungenkarzinom

Was ist gesichert in der Therapie?

Lung cancer

What has been confirmed in therapy?

  • Schwerpunkt: Was ist gesichert in der Therapie?
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Beim metastasierten, nichtkleinzelligen Lungenkarzinom sind mittlerweile viele Subtypen bekannt. Die fünf Säulen der Therapie sind die Chemotherapie, die antiangiogene Therapie, die molekular gezielte Therapie, die Immuntherapie und die frühe palliative Betreuung. Letztere Maßnahme sollte bei allen metastasierten Lungenkarzinomen angewendet werden, der Einsatz der anderen Therapiemodalitäten richtet sich nach dem histologischen Subtyp sowie nach immunhistochemischen und molekularpathologischen Eigenschaften des Tumors.

Abstract

Metastatic non-small cell lung cancer has now been subdivided into several subtypes. The five basic principles of treatment include chemotherapy, anti-angiogenic therapy, targeted therapy, immunotherapy and early palliative care. The latter should be implemented for all patients with metastatic lung cancer. The use of the other modalities depends on the histological subtype, as well as on the immunohistochemical and molecular features of the tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Attarwala H (2010) TGN1412: from discovery to disaster. J Young Pharm 2:332–336

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Bakitas M, Lyons KD, Hegel MT et al (2009) Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 302:741–749

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    Article  CAS  PubMed  Google Scholar 

  4. Brahmer J, Horn L, Jackman D (2017) Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors. In: AACR Annual Meeting. AACR, Washington DC, S CT77

    Google Scholar 

  5. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Bruckl WM, Wirtz RM, Bertsch T et al (2017) Liquid biopsy: detection of molecular markers for treatment decisions in lung cancer. Pneumologie 71:151–163

    Article  CAS  PubMed  Google Scholar 

  7. Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665. https://doi.org/10.1016/S0140-6736(14)60845-X

    Article  CAS  PubMed  Google Scholar 

  8. Heigener D, Gottfried M, Bennouna J et al (2016) Efficacy and safety of nintedanib/docetaxel in patients with lung adenocarcinoma: further analyses from the LUME-Lung 1 study. Ann Oncol 27:416–454

    Article  Google Scholar 

  9. Heigener DF, Reck M (2017) PD-1 axis inhibition in EGFR positives: a blunt sword? J Thorac Oncol 12:171–172

    Article  PubMed  Google Scholar 

  10. Herbst RS, Baas P, Kim DW et al (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

    Article  PubMed  Google Scholar 

  11. Lee CK, Man J, Lord S et al (2017) Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol 12:403–407

    Article  PubMed  Google Scholar 

  12. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  CAS  PubMed  Google Scholar 

  13. Mok T, Cheng Y, Xiandong Z et al (2017) Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): a randomized, open-label phase III trial. J Clin Oncol 35:abstr LBA9007. https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA9007

    Article  Google Scholar 

  14. Mok TS, Wu YL, Ahn MJ et al (2016) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640. https://doi.org/10.1056/NEJMoa1612674

    Article  PubMed  Google Scholar 

  15. Ou SH, Ahn JS, De Petris L et al (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668

    Article  CAS  PubMed  Google Scholar 

  16. Park K, Tan EH, Zhang L et al (2015) afatinib versus gefitinib as first-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Lux-Lung 7. In: ESMO ASIA Singapore.

    Google Scholar 

  17. Paz-Ares L, Socinski MA, Shahidi J et al (2016) Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol 27:1573–1579

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Paz-Ares LG, De Marinis F, Dediu M et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895–2902

    Article  CAS  PubMed  Google Scholar 

  19. Planchard D, Besse B, Groen HJ et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984–993

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155

    Article  CAS  PubMed  Google Scholar 

  21. Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833

    Article  CAS  PubMed  Google Scholar 

  22. Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265

    Article  PubMed  Google Scholar 

  23. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246

    Article  CAS  PubMed  Google Scholar 

  24. Scagliotti GV, Parikh P, Von PJ et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551

    Article  CAS  PubMed  Google Scholar 

  25. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  26. Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334

    Article  CAS  PubMed  Google Scholar 

  27. Shaw AT, Kim TM, Crino L et al (2017) Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:874–886

    Article  CAS  PubMed  Google Scholar 

  28. Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971

    Article  PubMed Central  PubMed  Google Scholar 

  29. Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–2062

    Article  CAS  PubMed  Google Scholar 

  30. Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177

    Article  PubMed  Google Scholar 

  31. Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742

    Article  CAS  PubMed  Google Scholar 

  32. Travis WD, Brambilla E, Noguchi M et al (2013) Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 137:668–684

    Article  PubMed  Google Scholar 

  33. Vansteenkiste JF, Cho BC, Vanakesa T et al (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:822–835

    Article  CAS  PubMed  Google Scholar 

  34. Wakelee H, Gadgeel S, Goldman J et al (2016) Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J Clin Oncol. https://doi.org/10.1200/JCO.2016.34.15_suppl.9001

    Google Scholar 

  35. Welker L, Galle J, Vollmer E (2004) Bronchological bioptic diagnosis of lung cancer—cytology and/or histology? Pneumologie 58:718–723

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkologischer Schwerpunkt, LungenClinic Grosshansdorf, Airway Research Center North, Wöhrendamm 80, 22927, Großhansdorf, Deutschland

    D. F. Heigener &  M. Reck

  2. Deutsches Zentrum für Lungenforschung, Großhansdorf, Deutschland

    D. F. Heigener &  M. Reck

Authors
  1. D. F. Heigener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Reck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. F. Heigener.

Ethics declarations

Interessenkonflikt

D.F. Heigener: Mitglied in wissenschaftlichen Beiräten und Honorare für Vorträge sowie Erstattung von Reisekosten von: Boehringer Ingelheim, Roche, Lilly, AstraZeneca, BMS, MSD und Pfizer. M. Reck: Mitglied in wissenschaftlichen Beiräten und Honorare für Vorträge sowie Erstattung von Reisekosten von: Roche Genentech, AstraZeneca, Pfizer, MSD, BMS, Boehringer Ingelheim, Novartis, Celgene und Lilly.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

H. Haller, Hannover

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heigener, D.F., Reck, M. Lungenkarzinom. Internist 58, 1258–1263 (2017). https://doi.org/10.1007/s00108-017-0339-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-017-0339-4

Schlüsselwörter

Keywords

Search

Navigation